Targets targeted by Sotorasib

Sotorasib (Sotorasib) is a targeted therapy drug targeting specific cancer gene mutations, mainly targeting KRAS G12C gene mutations. KRASThe gene is a key signaling molecule that regulates cell growth and differentiation. Under normal circumstances, it can accurately control the physiological processes of cells. However, when the KRAS gene undergoes a G12C mutation, it loses this normal regulatory ability, leading to abnormal cell proliferation and eventually the formation of cancer cells.

KRAS G12Cmutations are prevalent in a variety of cancers, including non-small cell lung cancer (NSCLC). The uniqueness of sotorasiib is that it can directly act on this specific mutated form of KRAS gene and interfere with the growth signaling pathway of cancer cells by inhibiting the activity of KRAS G12C mutation.

Sotorasiib binds to theKRAS G12C mutation, inhibits its activity and blocks interactions with other signaling molecules. This mechanism of action enables sotorasiib to specifically intervene in the abnormal cell proliferation caused by KRAS G12C mutation, thereby inhibiting the development of tumors.

The drug's targeted therapeutic mechanism allows it to show significant efficacy in some patients with KRAS G12Cmutated non-small cell lung cancer. The development of sotoracib represents a major breakthrough in the field of KRAS gene therapy, as scientists have long considered intervening directly in the KRAS gene to be an extremely challenging task.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original research version of sotorasibu in Hong Kong, China, as 120mg*240 tablets, is around 8 million, and the price of the European version of the original research version of the same specification as 4Around 10,000 yuan, the price is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.